We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Test Targets Pregnancy Disorder

By Labmedica staff writers
Posted on 16 Apr 2008
A new test can identify whether a mother and her baby have different blood types. The test is accurate, feasible, and it could significantly reduce unnecessary treatment.

If a mother's blood type is Rhesus- (Rh)-negative and she is carrying a baby whose blood is Rh-positive, complications can occur. Blood that is Rh-positive contains an RhD antigen that passes into the mother's blood during birth. This substance causes the mother to make antibodies against the RhD-positive blood. Problems do not occur during a woman's first pregnancy but, if the woman has another RhD-positive baby, the antibodies can cross the placenta and invade the baby's red blood cells. This results in hemolytic disease--a blood disorder that is serious and can cause death.

Generally, the blood type of pregnant women is determined at their first antenatal visit. If the woman is RhD-negative, she is given one or two antiserum injections of anti-RhD immunoglobulin during the pregnancy. However, because about 38% of RhD-negative women are carrying a baby who is also RhD-negative these women receive unnecessary treatment of antiserum injections.

To avoid unnecessary treatments scientists at the [UK] National Health System (NHS) Blood and Transplant Center in Bristol (UK; www.uktransplant.org.uk) studied a new way to predict a baby's blood group by typing its DNA in the plasma of RhD-negative pregnant women. "Our results show that fetuses of RhD-negative women could be RhD genotyped with an acceptable level of accuracy,” wrote the authors of an article describing the study, which appeared online in the British Medical Journal (BMJ) in April 2008. They also pointed out the low rate of false-positive results. "The introduction of fetal genotyping followed by the withholding of antenatal anti-RhD prophylaxis from mothers with an RhD-negative fetus would result in about 36% of women being saved from unnecessary exposure to human blood products, inconvenience, and discomfort.”


Related Links:
[UK] National Health System Blood and Transplant Centre

New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Lab Autoclave
T-Lab Eco
New
Dengue Virus Immunochromatographic Assay
STANDARD Q Dengue IgM/IgG Test

Latest Molecular Diagnostics News

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer